Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
93.90
-4.07 (-4.15%)
At close: Feb 27, 2026, 4:00 PM EST
93.99
+0.09 (0.10%)
After-hours: Feb 27, 2026, 7:38 PM EST
Guardant Health Revenue
In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth. Guardant Health had revenue of $281.27M in the quarter ending December 31, 2025, with 39.37% growth.
Revenue (ttm)
$982.02M
Revenue Growth
+32.88%
P/S Ratio
12.54
Revenue / Employee
$391,868
Employees
2,506
Market Cap
12.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Mettler-Toledo International | 4.03B |
| Charles River Laboratories International | 4.02B |
| Exact Sciences | 3.25B |
| Revvity | 2.86B |
GH News
- 1 day ago - Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 1 day ago - Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors - Seeking Alpha
- 8 days ago - Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions - Seeking Alpha
- 8 days ago - Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook - Business Wire
- 16 days ago - Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open - PRNewsWire
- 25 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 26 days ago - Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions - Business Wire